The Pharmaceutical Benefits Advisory Committee has recommended changes to the PBS eligibility criteria for both molnupiravir (Lagevrio®), and nirmatrelvir and ritonavir (Paxlovid®) effective Monday, 11 July 2022.
This decision is in response to the latest evidence on the effectiveness and safety of the medicines, the rate of uptake since they were made available on the PBS and the changing epidemiology of the virus.
Eligibility has been broadened to include people who have chronic respiratory issues due to conditions such as COPD, moderate or severe asthma and there is also greater access for adults living with disability who have multiple medical conditions.
Not being vaccinated has been removed as a risk factor from the criteria for prescription under the PBS.
The new eligibility includes updated age limits and risk factors summarised below. Treatment is now recommended if commenced within five days of symptoms for the following groups:
More information, including information targeting consumers, is available at https://www.health.gov.au/oral-treatments.